Skip to main content
Fig. 3 | Molecular Neurodegeneration

Fig. 3

From: Translational molecular imaging and drug development in Parkinson’s disease

Fig. 3

Established vs. experimental therapies in Parkinson’s disease (PD). While current drug PD therapy is primarily symptomatic and attempts to restore dopaminergic function, many lines of experimental research focus currently on the development of potentially disease-modifying concepts. The latter involve various targets that can be visualized using translational molecular imaging probes, thus providing the opportunity to conduct imaging-guided preclinical and clinical studies in PD. Among the promising concepts, preventing the formation of inclusion bodies by targeting misfolded α-synuclein, attenuating neuroinflammation via anti-tumor necrosis factor α (TNF-α) antibodies and glucagon-like peptide 1 (GLP-1) activation, as well as stimulation of autophagy with leucine-rich repeat kinase 2 (LRRK2) inhibitors have been suggested

Back to article page